{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:15:06Z","timestamp":1787314506299,"version":"build-2736575974"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2019,5,8]],"date-time":"2019-05-08T00:00:00Z","timestamp":1557273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,11,14]]},"abstract":"<jats:p>The aim of this study is to investigate the most frequent vaccine-preventable diseases for which IBD patients are hospitalized and thereby, contribute with evidence for vaccination guidelines. This study reports important data regarding the burden of HZV in patients with IBD.<\/jats:p>","DOI":"10.1093\/ibd\/izz093","type":"journal-article","created":{"date-parts":[[2019,5,8]],"date-time":"2019-05-08T11:59:26Z","timestamp":1557316766000},"page":"1966-1973","source":"Crossref","is-referenced-by-count":16,"title":["Vaccine-Preventable Diseases in Hospitalized Patients With Inflammatory Bowel Disease: A Nationwide Cohort Analysis"],"prefix":"10.1093","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0655-8606","authenticated-orcid":false,"given":"Daniela Guerrero","family":"Vinsard","sequence":"first","affiliation":[{"name":"Division of Internal Medicine, University of Connecticut Health Center, Farmington, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothy","family":"Wakefield","sequence":"additional","affiliation":[{"name":"Center on Aging, University of Connecticut Health Center, Farmington, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haleh","family":"Vaziri","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, University of Connecticut Health Center, Farmington, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffi","family":"Karagozian","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Tufts University School of Medicine, Boston, Massachusetts, USA"},{"name":"Division of Gastroenterology and Hepatology, Saint Francis Hospital, Hartford, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,5,8]]},"reference":[{"key":"2019111410284649100_CIT0001","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.15585\/mmwr.mm6542a3","article-title":"Prevalence of inflammatory bowel disease among adults aged \u226518 years - United States, 2015","volume":"65","author":"Dahlhamer","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"2019111410284649100_CIT0002","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1080\/00365521.2017.1286381","article-title":"Genetic risk factors for serious infections in inflammatory bowel diseases","volume":"52","author":"Sasidharan","year":"2017","journal-title":"Scand J Gastroenterol."},{"key":"2019111410284649100_CIT0003","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nrgastro.2015.34","article-title":"Epidemiology and risk factors for IBD","volume":"12","author":"Ananthakrishnan","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"2019111410284649100_CIT0004","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/ajg.2016.537","article-title":"ACG clinical guideline: preventive care in inflammatory bowel disease","volume":"112","author":"Farraye","year":"2017","journal-title":"Am J Gastroenterol."},{"key":"2019111410284649100_CIT0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41514-017-0020-0","article-title":"Fighting against a protean enemy: immunosenescence, vaccines, and healthy aging","volume":"4","author":"Del Giudice","year":"2018","journal-title":"NPJ Aging Mech Dis."},{"key":"2019111410284649100_CIT0006","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.gtc.2014.05.003","article-title":"Immunology of inflammatory bowel disease and molecular targets for biologics","volume":"43","author":"Dave","year":"2014","journal-title":"Gastroenterol Clin North Am."},{"key":"2019111410284649100_CIT0007","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1111\/j.1572-0241.2006.00646.x","article-title":"Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses","volume":"101","author":"Melmed","year":"2006","journal-title":"Am J Gastroenterol."},{"key":"2019111410284649100_CIT0008","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/01.MIB.0000437737.68841.87","article-title":"Immunization rates and vaccine beliefs among patients with inflammatory bowel disease: an opportunity for improvement","volume":"20","author":"Wasan","year":"2014","journal-title":"Inflamm Bowel Dis."},{"key":"2019111410284649100_CIT0009","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/apt.12182","article-title":"Increased risk of herpes zoster among 108 604 patients with inflammatory bowel disease","volume":"37","author":"Long","year":"2013","journal-title":"Aliment Pharmacol Ther."},{"key":"2019111410284649100_CIT0010","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/ajg.2012.406","article-title":"Increased risk of pneumonia among patients with inflammatory bowel disease","volume":"108","author":"Long","year":"2013","journal-title":"Am J Gastroenterol."},{"key":"2019111410284649100_CIT0011","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/ijcp.12508","article-title":"Increased risk of varicella zoster virus infection in inflammatory bowel disease in an Asian population: a nationwide population-based cohort study","volume":"69","author":"Tsai","year":"2015","journal-title":"Int J Clin Pract."},{"key":"2019111410284649100_CIT0012","first-page":"540","article-title":"Vaccinating patients with inflammatory bowel disease","volume":"12","author":"Reich","year":"2016","journal-title":"Gastroenterol Hepatol (N Y)."},{"key":"2019111410284649100_CIT0013","first-page":"717","article-title":"Vaccination and health maintenance issues to consider in patients with inflammatory bowel disease","volume":"13","author":"Reich","year":"2017","journal-title":"Gastroenterol Hepatol (N Y)."},{"key":"2019111410284649100_CIT0014","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1086\/587063","article-title":"Vaccination in patients with chronic rheumatic or autoimmune diseases","volume":"46","author":"Gl\u00fcck","year":"2008","journal-title":"Clin Infect Dis."},{"key":"2019111410284649100_CIT0015","first-page":"95","article-title":"Varicella-zoster virus infection: natural history, clinical manifestations, immunity and current and future vaccination strategies","volume":"41","author":"Freer","year":"2018","journal-title":"Rev New Microbiol."},{"key":"2019111410284649100_CIT0016","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1080\/13696998.2016.1187150","article-title":"Healthcare resource utilization and costs associated with herpes zoster in the US","volume":"19","author":"Johnson","year":"2016","journal-title":"J Med Econ."},{"key":"2019111410284649100_CIT0017","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/jama.291.7.851","article-title":"Effectiveness over time of varicella vaccine","volume":"291","author":"V\u00e1zquez","year":"2004","journal-title":"JAMA."},{"key":"2019111410284649100_CIT0018","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1056\/NEJMoa013441","article-title":"Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants","volume":"347","author":"Hata","year":"2002","journal-title":"N Engl J Med."},{"key":"2019111410284649100_CIT0019","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1086\/651199","article-title":"Influence of age and nature of primary infection on varicella-zoster virus-specific cell-mediated immune responses","volume":"201","author":"Weinberg","year":"2010","journal-title":"J Infect Dis."},{"key":"2019111410284649100_CIT0020","first-page":"341","article-title":"VZV T cell-mediated immunity","volume":"342","author":"Weinberg","year":"2010","journal-title":"Curr Top Microbiol Immunol."},{"key":"2019111410284649100_CIT0021","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/j.cgh.2006.09.019","article-title":"Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease","volume":"4","author":"Gupta","year":"2006","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2019111410284649100_CIT0022","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1093\/ibd\/izx115","article-title":"The severity of herpes zoster in inflammatory bowel disease patients treated with anti-TNF agents","volume":"24","author":"Khan","year":"2018","journal-title":"Inflamm Bowel Dis."},{"key":"2019111410284649100_CIT0023","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/MCG.0000000000000086","article-title":"The appropriate use of vaccines in patients with inflammatory bowel disease","volume":"48","author":"Lodhia","year":"2014","journal-title":"J Clin Gastroenterol."},{"key":"2019111410284649100_CIT0024","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1093\/cid\/cit684","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin Infect Dis."},{"key":"2019111410284649100_CIT0025","article-title":"Morbidity and mortality weekly report recommendations of the advisory committee on immunization practices for use of herpes zoster vaccines","volume":"67","author":"Dooling","year":"2018","journal-title":"MMWR."},{"key":"2019111410284649100_CIT0026","doi-asserted-by":"crossref","first-page":"11273","DOI":"10.3748\/wjg.v21.i40.11273","article-title":"Immunogenicity and mechanisms impairing the response to vaccines in inflammatory bowel disease","volume":"21","author":"Mar\u00edn","year":"2015","journal-title":"World J Gastroenterol."},{"key":"2019111410284649100_CIT0027","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.cgh.2007.02.035","article-title":"Immune response to influenza vaccine in pediatric patients with inflammatory bowel disease","volume":"5","author":"Mamula","year":"2007","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2019111410284649100_CIT0028","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/ibd.21706","article-title":"Immunogenicity and safety of influenza vaccination in children with inflammatory bowel disease","volume":"18","author":"deBruyn","year":"2012","journal-title":"Inflamm Bowel Dis."},{"key":"2019111410284649100_CIT0029","first-page":"S","article-title":"Vaccination outcomes in inflammatory bowel disease exposure to anti-TNF\u03b1 therapy in the third trimester of pregnancy is not associated with increased adverse outcomes: results from the PIANO registry","volume":"146","author":"Abdallah","year":"2014","journal-title":"Gastroenterology."},{"key":"2019111410284649100_CIT0030","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1053\/j.gastro.2014.10.038","article-title":"American gastroenterological association institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy","volume":"148","author":"Perrillo","year":"2015","journal-title":"Gastroenterology."},{"key":"2019111410284649100_CIT0031","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1007\/s10620-018-5042-3","article-title":"Hepatitis B virus screening and reactivation in a national VA cohort of patients with inflammatory bowel disease treated with tumor necrosis factor antagonists","volume":"63","author":"Shah","year":"2018","journal-title":"Dig Dis Sci."}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ibdjournal\/article-pdf\/25\/12\/1966\/30746028\/izz093.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ibdjournal\/article-pdf\/25\/12\/1966\/30746028\/izz093.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,14]],"date-time":"2019-11-14T10:29:11Z","timestamp":1573727351000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/25\/12\/1966\/5487145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,8]]},"references-count":31,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2019,5,8]]},"published-print":{"date-parts":[[2019,11,14]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izz093","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,12]]},"published":{"date-parts":[[2019,5,8]]}}}